Page last updated: 2024-08-22

buthionine sulfoximine and Bone Marrow Diseases

buthionine sulfoximine has been researched along with Bone Marrow Diseases in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Anderson, CP; Bleyer, WA; Cairncross, JG; Cloughesy, T; Doolittle, ND; Eck, SL; Guastadisegni, P; Hall, WA; Muldoon, LL; Neuwelt, EA; Patel, SJ; Peereboom, D; Siegal, T	1
Deloughery, TG; Hasler, BP; Muldoon, LL; Neuwelt, EA; Pagel, MA	1

Other Studies

2 other study(ies) available for buthionine sulfoximine and Bone Marrow Diseases

Article	Year
Importance of dose intensity in neuro-oncology clinical trials: summary report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium. Neuro-oncology, 2001, Volume: 3, Issue:1 Topics: Adult; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Bone Marrow Diseases; Bone Marrow Transplantation; Brain Neoplasms; Buthionine Sulfoximine; Child; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Cognition Disorders; Combined Modality Therapy; Cranial Irradiation; Dose-Response Relationship, Drug; Drug Synergism; Genetic Therapy; Genetic Vectors; Glioma; Glutathione; Guinea Pigs; Hearing Loss, Sensorineural; Hematopoietic Stem Cell Transplantation; Humans; Hypertonic Solutions; Lymphoma, Non-Hodgkin; Meningeal Neoplasms; Multicenter Studies as Topic; Neuroblastoma; Oligodendroglioma; Permeability; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome	2001
Therapeutic efficacy of aortic administration of N-acetylcysteine as a chemoprotectant against bone marrow toxicity after intracarotid administration of alkylators, with or without glutathione depletion in a rat model. Cancer research, 2001, Nov-01, Volume: 61, Issue:21 Topics: Acetylcysteine; Animals; Antimetabolites; Antineoplastic Agents, Alkylating; Aorta, Thoracic; Blood-Brain Barrier; Bone Marrow Diseases; Brain; Brain Neoplasms; Buthionine Sulfoximine; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Interactions; Female; Glutathione; Infusions, Intra-Arterial; Lung Neoplasms; Rats; Rats, Long-Evans; Tissue Distribution; Xenograft Model Antitumor Assays	2001

Article

Year

Importance of dose intensity in neuro-oncology clinical trials: summary report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium.

Neuro-oncology, 2001, Volume: 3, Issue:1

Topics: Adult; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Bone Marrow Diseases; Bone Marrow Transplantation; Brain Neoplasms; Buthionine Sulfoximine; Child; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Cognition Disorders; Combined Modality Therapy; Cranial Irradiation; Dose-Response Relationship, Drug; Drug Synergism; Genetic Therapy; Genetic Vectors; Glioma; Glutathione; Guinea Pigs; Hearing Loss, Sensorineural; Hematopoietic Stem Cell Transplantation; Humans; Hypertonic Solutions; Lymphoma, Non-Hodgkin; Meningeal Neoplasms; Multicenter Studies as Topic; Neuroblastoma; Oligodendroglioma; Permeability; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome

2001

Therapeutic efficacy of aortic administration of N-acetylcysteine as a chemoprotectant against bone marrow toxicity after intracarotid administration of alkylators, with or without glutathione depletion in a rat model.

Cancer research, 2001, Nov-01, Volume: 61, Issue:21

Topics: Acetylcysteine; Animals; Antimetabolites; Antineoplastic Agents, Alkylating; Aorta, Thoracic; Blood-Brain Barrier; Bone Marrow Diseases; Brain; Brain Neoplasms; Buthionine Sulfoximine; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Interactions; Female; Glutathione; Infusions, Intra-Arterial; Lung Neoplasms; Rats; Rats, Long-Evans; Tissue Distribution; Xenograft Model Antitumor Assays

2001